Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon, Inc. recently updated its clinical study on IMNN-101, a DNA vaccine targeting SARS-CoV-2. Officially titled ‘Phase 1/2, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a DNA Vaccine, IMNN-101,’ the study aims to assess the safety and immune response of the vaccine in adults previously vaccinated against COVID-19. This study is significant as it explores the potential of a new vaccine formulation to enhance protection against emerging variants.
The intervention being tested is IMNN-101, a biological DNA vaccine designed to encode the spike antigen of the SARS-CoV-2 Omicron XBB.1.5 variant. The vaccine is administered intramuscularly and aims to boost immunity in previously vaccinated individuals.
The study follows an interventional, single-group design with no masking, focusing on prevention. Participants receive a single dose of the vaccine, and the study progresses through a dose-escalation model to determine the optimal dose for Phase 2.
The study began on June 4, 2024, with primary completion expected by mid-2025. The latest update was submitted on July 22, 2025, indicating ongoing data analysis and review.
This update could influence Imunon’s stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the vaccine market. Investors should monitor further developments closely.
The study is ongoing, with more details available on the ClinicalTrials portal.